{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:08:22Z","timestamp":1794017302543,"version":"4.8.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jaad.2017.06.043","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T09:42:45Z","timestamp":1515750165000},"page":"383-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation"],"prefix":"10.1016","volume":"78","author":[{"given":"Scott M.","family":"Whitlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton W.","family":"Enos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.06.043_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2016.08.022","article-title":"Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study","volume":"76","author":"Kim","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib2","first-page":"962","article-title":"Increased occurrence of psoriasis in patients with Crohn's disease and their relatives","volume":"85","author":"Lee","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn's disease","volume":"23","author":"Cohen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.06.043_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between\u00a0psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaad.2017.06.043_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaad.2017.06.043_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ajhg.2009.01.026","article-title":"Diverse genome-wide association studies associate the IL12\/IL23 pathway with Crohns disease","volume":"84","author":"Wang","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.jaad.2017.06.043_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2017.06.043_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2017.06.043_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2133.2009.09348.x","article-title":"Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjd.14061","article-title":"Psoriasis flare with corticosteroid use in psoriatic arthritis","volume":"174","author":"Coates","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7183","key":"10.1016\/j.jaad.2017.06.043_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.318.7183.593","article-title":"Clinical guidelines: developing guidelines","volume":"318","author":"Shekelle","year":"1999","journal-title":"BMJ"},{"issue":"9494","key":"10.1016\/j.jaad.2017.06.043_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2017.06.043_bib15","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib17","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for\u00a0induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib19","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the\u00a0treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib23","doi-asserted-by":"crossref","first-page":"S-804","DOI":"10.1016\/S0016-5085(12)63121-7","article-title":"Tu1327a golimumab for treatment of moderate to severe anti-TNF refractory crohn's disease: open label experience","volume":"142","author":"Ben-Bassat","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients\u00a0with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib28","doi-asserted-by":"crossref","first-page":"S-75","DOI":"10.1016\/S0016-5085(12)60287-X","article-title":"326 Assessment of the efficacy and safety of certolizumab pegol for the\u00a0treatment of moderate to severe ulcerative colitis","volume":"142","author":"Lee","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib29","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib30","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib31","first-page":"990","article-title":"Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2017.06.043_bib32","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O'Toole","year":"2016","journal-title":"J Dig Dis Sci"},{"issue":"9625","key":"10.1016\/j.jaad.2017.06.043_bib33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"9664","key":"10.1016\/j.jaad.2017.06.043_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/2050640615616068","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"9999","key":"10.1016\/j.jaad.2017.06.043_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients\u00a0with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2017.06.043_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"26","key":"10.1016\/j.jaad.2017.06.043_bib39","first-page":"2534","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"373","author":"van de Kerkhoff","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"9993","key":"10.1016\/j.jaad.2017.06.043_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review article: defining remission in ulcerative colitis","volume":"34","author":"Travis","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease\u00a0severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib44","series-title":"Inflectra (infliximab-dyyb): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib45","series-title":"Amjevita (adalimumab-atto): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib46","series-title":"Erelzi (etanercept-szzs): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib47","series-title":"Remicade (infliximab): full prescribing information","year":"2010"},{"key":"10.1016\/j.jaad.2017.06.043_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib49","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jaad.2017.06.043_bib50","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib52","first-page":"CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing\u00a0and maintaining remission in Crohn's disease: a\u00a0network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.jaad.2017.06.043_bib54","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3748\/wjg.v21.i19.6044","article-title":"Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis","volume":"21","author":"Mei","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib55","series-title":"Humira (adalimumab): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2017.06.043_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2017.06.043_bib59","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib60","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2017.06.043_bib61","series-title":"Simponi (golimumab): full prescribing information","year":"2016"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib63","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.13291","article-title":"Randomized clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis","volume":"42","author":"Rutgeerts","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2017.06.043_bib64","series-title":"Cimzia (certolizumab pegol): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/apt.12930","article-title":"Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study","volume":"40","author":"Sandborn","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib68","series-title":"Enbrel (etanercept): full prescribing information","year":"2013"},{"key":"10.1016\/j.jaad.2017.06.043_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2017.06.043_bib70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib71","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active\u00a0Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2017.06.043_bib72","series-title":"Stelara (ustekinumab): full prescribing information","year":"2016"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib74","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jaad.2017.06.043_bib75","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib76","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/S0016-5085(16)33398-4","article-title":"Tu2006 ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe crohn's disease: results from the UNITI and IMUNITI phase 3 clinical trial","volume":"150","author":"Sands","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2017.06.043_bib77","series-title":"Cosentyx (secukinumab): full prescribing information","year":"2016"},{"issue":"12","key":"10.1016\/j.jaad.2017.06.043_bib78","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib79","first-page":"821","article-title":"Secukinumab Improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib80","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib81","series-title":"Taltz (ixekizumab): full prescribing information","year":"2016"},{"key":"10.1016\/j.jaad.2017.06.043_bib82","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib83","first-page":"AB24","article-title":"Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER trials): adjudicated data from the induction period","volume":"74","author":"Langley","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib84","unstructured":"Valeant. Siliq (brodalumab): full prescribing information 2017. Available at: http:\/\/www.valeant.com\/Portals\/25\/Pdf\/PI\/Siliq-pi.pdf. Accessed November 12, 2017."},{"issue":"14","key":"10.1016\/j.jaad.2017.06.043_bib85","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib87","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40261-017-0500-9","article-title":"Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis","volume":"37","author":"Attia","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"24","key":"10.1016\/j.jaad.2017.06.043_bib88","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"11","key":"10.1016\/j.jaad.2017.06.043_bib90","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib91","unstructured":"Janssen Biotech. Tremfya (guslekumab): full prescribing information. 2017. Available at: https:\/\/www.tremfyahcp.com\/pdf\/PrescribingInformation.pdf. Accessed November 12, 2017."},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib93","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib94","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.06.043_bib95","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib96","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib97","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM198909283211301","article-title":"A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's Disease","volume":"321","author":"Brynskov","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib98","first-page":"CD000297","article-title":"Cyclosporine for induction of remission in Crohn's disease","author":"McDonald","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2017.06.043_bib99","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00054725-200403000-00002","article-title":"Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis","volume":"10","author":"Arts","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib101","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine vs. intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","author":"D'Haens","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2017.06.043_bib102","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety\u00a0results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients\u00a0with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib103","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis (TICOPA) study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib104","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib105","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib106","doi-asserted-by":"crossref","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2017.06.043_bib107","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.043_bib108","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis","volume":"150","author":"Carbonell","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis over 52 Weeks: a phase III, randomized Controlled Trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib111","series-title":"Soriatane (acitretin): full prescribing information","year":"2004"},{"key":"10.1016\/j.jaad.2017.06.043_bib112","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/09546634.2011.588192","article-title":"Efficacy of low-dose acitretin in the treatment of psoriasis","volume":"23","author":"Haushalter","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2017.06.043_bib114","series-title":"Neoral (cyclosporine):full prescribing information","year":"2015"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib116","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2133.1996.tb03885.x","article-title":"Anti-inflammatory efficacy of low-dose Cyclosporin A in psoriatic arthritis: a prospective multicenter study","volume":"135","author":"Mahrle","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib117","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A randomized, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis","volume":"64","author":"Fraser","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib119","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib120","first-page":"341","article-title":"Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis","volume":"29","author":"Feuerstein","year":"2016","journal-title":"Ann Gastroenterol"},{"issue":"22","key":"10.1016\/j.jaad.2017.06.043_bib121","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of\u00a0methotrexate with placebo for the maintenance of remission in Crohn's disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.043_bib122","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib123","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn's disease","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib124","first-page":"CD006618","article-title":"Methotrexate for induction of remission in ulcerative colitis","author":"Chande","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2017.06.043_bib125","series-title":"Otezla (apremilast): full prescribing information","year":"2015"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib126","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaad.2017.06.043_bib127","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2017.06.043_bib128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1067\/mjd.2000.104890","article-title":"Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil","volume":"42","author":"Grundmann-Kollmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.jaad.2017.06.043_bib129","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3748\/wjg.15.1594","article-title":"Use of mycophenolate mofetil in inflammatory bowel disease","volume":"15","author":"Tan","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.44.5.625","article-title":"Randomised trial\u00a0of\u00a0mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease","volume":"44","author":"Neurath","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2017.06.043_bib131","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archderm.1990.01670280071013","article-title":"Sulfasalazine improves psoriasis: a double-blind analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.06.043_bib132","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2017.06.043_bib133","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(65)90972-4","article-title":"Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis","volume":"1","author":"Misiewicz","year":"1965","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2017.06.043_bib134","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.14.12.923","article-title":"A controlled therapeutic trial of\u00a0long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)","volume":"14","author":"Dissanayake","year":"1973","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2133.1989.tb08198.x","article-title":"Hydroxyurea in the management of therapy resistant psoriasis","volume":"121","author":"Layton","year":"1989","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.043_bib136","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-4362.2001.01255.x","article-title":"Rediscovering hydroxyurea: its role in recalcitrant psoriasis","volume":"40","author":"Kumar","year":"2001","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.043_bib137","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/09546630701499291","article-title":"Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study","volume":"18","author":"Ranjan","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"5897","key":"10.1016\/j.jaad.2017.06.043_bib138","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/bmj.1.5897.49","article-title":"Treatment of psoriasis with azathioprine","volume":"1","author":"Du Vivier","year":"1974","journal-title":"Br Med J"},{"issue":"5703","key":"10.1016\/j.jaad.2017.06.043_bib139","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/bmj.2.5703.237-b","article-title":"Azathioprine in psoriasis","volume":"2","author":"Greaves","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2017.06.043_bib140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00124743-200106000-00005","article-title":"The long-term use of azathioprine in patients with psoriatic arthritis","volume":"7","author":"Lee","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib141","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2017.06.043_bib142","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","article-title":"Controlled trial of azathioprine in Crohn's disease","volume":"2","author":"Willoughby","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2017.06.043_bib143","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF01070829","article-title":"A controlled trial of azathioprine in Crohn's disease","volume":"20","author":"Rosenberg","year":"1975","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.jaad.2017.06.043_bib144","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/bmj.284.6325.1291","article-title":"Controlled trial of azathioprine in chronic ulcerative colitis","volume":"284","author":"Kirk","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib145","first-page":"14","article-title":"Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial","volume":"19","author":"Sood","year":"2000","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib146","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","article-title":"A prospective randomized observer-blind 2-year trial of azathioprine monotherapy vs. azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis","volume":"99","author":"Mantzaris","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib147","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1440-0960.1988.tb00391.x","article-title":"Treatment of psoriasis with 6-thioguanine","volume":"29","author":"Zackheim","year":"1988","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.043_bib148","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0190-9622(94)70055-9","article-title":"6-Thioguanine treatment of psoriasis: experience in 81 patients","volume":"30","author":"Zackheim","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.043_bib149","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mjd.2001.109296","article-title":"Thioguanine for refractory psoriasis: a 4-year experience","volume":"44","author":"Mason","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2036.2003.01440.x","article-title":"6-thioguanine\u2013efficacy and safety in chronic active Crohn's disease","volume":"17","author":"Herrlinger","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2017.06.043_bib151","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ibd.20492","article-title":"Further experience with the use of 6-thioguanine in patients with Crohn's disease","volume":"14","author":"Ansari","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.jaad.2017.06.043_bib152","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/00365520510023369","article-title":"A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis","volume":"40","author":"Teml","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib153","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archderm.1996.03890280081011","article-title":"Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study: the European FK 506 multicenter psoriasis study group","volume":"132","author":"Bos","year":"1996","journal-title":"Arch Dermatol"},{"issue":"1 suppl 95","key":"10.1016\/j.jaad.2017.06.043_bib154","first-page":"S12","article-title":"Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure","volume":"34","author":"Lythgoe","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib155","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1572-0241.1998.539_g.x","article-title":"Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)","volume":"93","author":"Fellermann","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2017.06.043_bib156","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.043_bib157","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of\u00a0leflunomide in the treatment of psoriatic arthritis and\u00a0psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib158","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10620-007-9953-7","article-title":"Treatment of\u00a0Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety","volume":"53","author":"Holtmann","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2017.06.043_bib159","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of\u00a0fumaric acid derivatives: results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.043_bib160","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.043_bib161","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for psoriatic arthritis: a randomized, double-blind, placebo-controlled study","volume":"31","author":"Peeters","year":"1992","journal-title":"Br J Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221731945X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221731945X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:58Z","timestamp":1759272358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221731945X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":161,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S019096221731945X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.06.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}